Evidence map›Paper›PMID 36083314›Full record

ArticleEuropean journal of pediatrics2022

Increased use of high-flow nasal cannulas after the pandemic in bronchiolitis: a more severe disease or a changed physician's attitude?

Sergio Ghirardo, Giorgio Cozzi, Giovanna Tonin, Francesco Maria Risso, Laura Dotta, Alessandro Zago, Daniela Lupia, Paola Cogo, Nicola Ullmann, Antonella Coretti and 4 more

Open access · hybridAbstract read
In one paragraph

Article in European journal of pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Severe respiratory syncytial virus disease.Journal of intensive medicine · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Sergio GhirardoUnit of Pediatrics, Department of Medicine, University Hospital S. Maria della Misericordia, Viale San Daniele 27, Udine, Italy. ghirardo.sergio@gmail.com.ORCID http://orcid.org/0000-0002-6329-4208
Giorgio CozziInstitute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, Italy.
Giovanna ToninDepartment of Medicine, DAME, University of Udine, Udine, Italy.
Francesco Maria RissoNeonatal Intensive Care Unit, Children's Hospital, ASST Spedali Civili di Brescia, Brescia, Italy.
Laura DottaDepartment of Pediatrics, Università di Brescia, Istituto di Medicina Molecolare Angelo Nocivelli", ASST Spedali Civili, Brescia, Italy.
Alessandro ZagoUniversity of Trieste, Trieste, Italy.
Daniela LupiaPediatric Pulmonology & Respiratory Intermediate Care Unit, Clinical, Management and Technology Innovation Research Unit, Academic Department of Pediatrics, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Paola CogoUnit of Pediatrics, Department of Medicine, University Hospital S. Maria della Misericordia, Viale San Daniele 27, Udine, Italy.
Nicola UllmannPediatric Pulmonology & Respiratory Intermediate Care Unit, Clinical, Management and Technology Innovation Research Unit, Academic Department of Pediatrics, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Antonella CorettiPediatric Pulmonology & Respiratory Intermediate Care Unit, Clinical, Management and Technology Innovation Research Unit, Academic Department of Pediatrics, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Raffaele BadolatoDepartment of Pediatrics, Università di Brescia, Istituto di Medicina Molecolare Angelo Nocivelli", ASST Spedali Civili, Brescia, Italy.
Alessandro AmaddeoInstitute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, Italy.ORCID http://orcid.org/0000-0003-2117-0781
Egidio BarbiInstitute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, Italy.ORCID http://orcid.org/0000-0002-6343-846X
Renato CutreraPediatric Pulmonology & Respiratory Intermediate Care Unit, Clinical, Management and Technology Innovation Research Unit, Academic Department of Pediatrics, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.ORCID http://orcid.org/0000-0001-7711-5672
Bambino Gesù Children's Hospital · ITIRCCS Materno Infantile Burlo Garofolo · ITUniversity of Brescia · ITUniversity of Trieste · ITUniversity of Udine · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITOspedale Santa Maria della Misericordia di Udine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After the SARS-CoV-2 pandemic, we noticed a marked increase in high-flow nasal cannula use for bronchiolitis. This study aims to report the percentage of children treated with high-flow nasal cannula (HFNC) in various seasons. The secondary outcomes were admissions for bronchiolitis, virological results, hospital burden, and NICU/PICU need. We conducted a retrospective study in four Italian hospitals, examining the medical records of all infants (< 12 months) hospitalized for bronchiolitis in the last four winter seasons (1 September-31 March 2018-2022). In the 2021-2022 winter season, 66% of admitted children received HFNC versus 23%, 38%, and 35% in the previous 3 years. A total of 876 patients were hospitalized in the study periods. In 2021-2022, 300 infants were hospitalized for bronchiolitis, 22 in 2020-2021, 259 in 2019-2020, and 295 in 2018-2019. The percentage of patients needing intensive care varied from 28.7% to 18%, 22%, and 15% in each of the four considered periods (p < 0.05). Seventy-seven percent of children received oxygen in the 2021-2022 winter; vs 50%, 63%, and 55% (p < 0.01) in the previous 3 years. NIV/CPAP was used in 23%, 9%, 16%, and 12%, respectively. In 2021-2020, 2% of patients were intubated; 0 in 2020-2021, 3% in 2019-2020, and 1% in 2018-2019.

conclusionThis study shows a marked increase in respiratory support and intensive care admissions this last winter. While these severity indexes were all driven by medical choices, more reliable indexes such as intubation rate and length of stay did not change. Therefore, we suggest that there is a more aggressive treatment attitude rather than a more severe disease. WHAT IS KNOWN: • COVID-19 pandemic deeply impacted bronchiolitis epidemiology, reducing hospitalizations to onetenth. In the 2021-2022 winter, bronchiolitis resurged to pre-pandemic numbers in Europe. WHAT IS NEW: • Bronchiolitis hospitalization rose much faster in the 2021-2022 winter period, peaking at a higher level. Respiratory supports and high-flow nasal cannula increased significantly compared to the pre-pandemic era.

Indexed as

BronchiolitisCOVID-19PhysiciansAttitude of Health PersonnelCannulaChildHumansInfantOxygenOxygen Inhalation TherapyPandemicsRetrospective StudiesSARS-CoV-2OxygenBronchiolitisCOVID-19 pandemicHigh-flow nasal cannula (HFNC)Non-invasive ventilation (NIV)Respiratory syncytial virus (RSV)

Identifiers

PMID36083314
PMCPMC9458479
OpenAlexW4295087971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.